Ocugen Inc (OCGN)

[sgunderbarth]

“Project NextGen will also support 10 to 15 phase 1 trials and 6 to 8 phase 2 trials at the NIAID, Beigel said. Companies will provide their vaccine candidates, while the NIAID will cover the costs of the trials.”

“Ocugen is the other company that has publicized its vaccine’s selection for NIAID trials. Its mucosal vaccine uses a chimp adenovirus to deliver the SARS-CoV-2 spike protein. Although the vaccine hasn’t yet been tested in humans in the US, it has completed phase 1, 2, and 3 trials in India, where, in the form of nose drops, it was authorized more than a year ago as a primary vaccine as well as a mix-and-match booster.”

https://jamanetwork.com/journals/jama/fullarticle/2812830

OCGN